inPROBE

17/05/2024

NEW BLOG POST
🇬🇧 ® technological platform was designed to determine protein expression in a way different from the standard one. The determination is performed in vivo, directly in the patient's body, without needing to collect tissue. The result is obtained in real-time and it is quantitative, so it is an objective result, expressed in numbers. After summarizing the I part of the clinical trials, we should turn our attention to further areas of application of the breakthrough technology.
Read full article👉 https://sdsoptic.pl/en/promising-perspectives-for-the-application-of-inprobe-technology-platform-for-protein-expression-determination/

An inherent feature of modern oncology is personalization, manifested in conversion from the fit-to-all strategy based on applying the same chemotherapy regimens to all patients with a specific type of cancer to therapy tailored to the individual patient’s situation.An integral part of personaliza...

23/02/2024

Recently the SDS Optic announce really exiting news! The company received positive results from the first part of the inPROBE®️ clinical trial
ℹ️ Statistical report after the first part of the clinical trial, confirmed the safety of use in human and achievement of the primary endpoint of the study in terms of the initial determining correlation of the range of concentrations measured with the inPROBE® microprobe in reference to the expression of the HER2 biomarker measured with traditional methods (IHC/FISH).
❞ Medical Liason at SDS Optic S.A. Dr. Dariusz Stencel MBA, who supports us in effective implementation of clinical trials, says: "The results confirm the effectiveness and safety of inPROBE. The microprobe could be an additional diagnostic tool for oncologists, enabling faster and more precise molecular diagnostics in patients with breast cancer, which is still the main cause of cancer incidence and the second cause of cancer-related mortality in women in Poland. With great energy, we are starting preparations for the second part of the study, where we plan to involve 192 patients and which will certainly provide new, interesting data.”

_______________
European Commission EIT Health CORDIS_EU ESMO - European Society for Medical Oncology Enterprise Europe Network World Health Organization (WHO) EIC - The European Innovation Council European Investment Bank BioBus The Curtis - Philadelphia BioLabs City of Philadelphia Government

22/11/2023

23/10/2023

⭐️Magdalena Staniszewska, PHD, DSC, Professor KUL with a poster presentation at (ESMO - European Society for Medical Oncology) in Madrid (Spain) titled: "Novel in vivo photonics-immunoassay system, , for the rapid detection of HER2 in "
👉Professor Magdalena Staniszewska needs no introduction. She is an outstanding scientist, co-creator of the inPROBE technology. Co-founder and Chief R&D Officer at SDS Optic Inc. She supervises and coordinates work in the field of , and . She is also the Head of the Company's Scientific Advisory Board.
ℹ️The ESMO Congress is a highly influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.

03/10/2023

🇪🇺 EIB will support SDS Optic and platform technology with EUR 10 million❗️
ARTICLE: 🔗 https://sdsoptic.pl/en/eib-to-support-sds-optic/
EIB PRESS RELEASE 🔗 https://www.eib.org/en/press/all/2023-358-investeu-poland-eib-supports-sds-optic-in-scaling-up-its-cancer-detection-technology

ℹ️ October 2, 2023 SDS Optic Inc., publicly listed at GPW / Giełda Papierów Wartościowych w Warszawie / Warsaw Stock Exchange (NC:SDS), concluded EUR 10 million venture debt finance agreement with the European Investment Bank (EIB) under the InvestEU Fund for inPROBE® novel biosensing platform technology scale-up research and development.

🇵🇱
🇪🇺 EBI wesprze SDS Optic kwotą 10 mln EUR❗️
ARTYKUŁ 🔗 https://sdsoptic.pl/ebi-wesprze-sds-optic-kwota-10-mln-eur/
WIDEO 🔗 https://youtu.be/xy4uphZKQsk

ℹ️ 2 października 2023 r. SDS Optic S.A. zawarła umowę finansowania typu venture debt na kwotę do 10 mln euro z Europejskim Bankiem Inwestycyjnym (EBI) w ramach programu InvestEU Research Innovation and Digitalisation Window (RIDW) 1.1. na badania, rozwój i komercjalizację przełomowej platformy technologicznej inPROBE®

_______________
European Commission EIC - The European Innovation Council EIT Health
Polish Medical Devices - Branżowy Program Promocji

08/09/2023

BMJ Journal: "the rising tide of early-onset cancers demands attention"

A new publication in the confirms the increasing number of cancer cases among people under age 50.
New cases of early-onset cancers have increased by over 79% since 1990.

Much more of the young people suffer from cancer types, which just until recently were considered typical in older age groups. These include breast, tracheal, bronchus and lung, stomach and colorectal cancers.

Scientists estimate that by 2030, the number of new cases of early cancers will increase by 31%, and at the same time the mortality rate will increase by 21%.

This is another evidence from the world of science that confirms that in addition to early diagnostics, devices such as inPROBE are essential for improve the accuracy of cancer diagnostics (detection of specific cancer molecules) and increase the targeted therapies effectiveness (drug delivery monitoring). SDS Optic 💪

ℹ️🔗 https://bmjoncology.bmj.com/content/2/1/e000049

26/06/2023

➡️We are starting technological cooperation with Philips Engineering Solutions and the CSEM research and development institute from Switzerland.
➡️ As part of the consortium created for this purpose, with SDS Optic S.A. as a leader and coordinator, we obtained funding in the amount of up to EUR 244.09 (approx. PLN 1.1 million) as part of the project, financed by the European Commission.
➡️ Our plan is to scale up, from the level of a clinical prototype to the level of a commercial and industrial prototype, the analyzer (detection device) owned by the SDS Optic, used for analyzing and measuring with disposable ® microprobes.

➡️Rozpoczynamy współpracę technologiczną z koncernem Philips Engineering Solutions oraz instytutem badawczo-rozwojowym CSEM.

➡️ W ramach utworzonego w tym celu konsorcjum, z SDS Optic S.A. w roli lidera i koordynatora, pozyskaliśmy dofinansowanie w kwocie do 244,09 EUR (ok. 1,1 mln PLN) w ramach projektu , finansowanego przez Komisję Europejską (European Commission ).

➡️ Wspólnie planujemy przeskalować, z poziomu prototypu klinicznego do poziomu prototypu komercyjnego i przemysłowego, posiadany przez Spółkę analizator (urządzenie detekcyjne), służące do analizy i pomiarów badań przy użyciu jednorazowych mikrosond inPROBE ®.

➡️ Więcej w artykule: https://sdsoptic.pl/sds-optic-s-a-rozpoczyna-wspolprace-technologiczna-z-koncernem-philipsoraz-instytutem-badawczo-rozwojowym-csem/

lub w raporcie ESPI: 🔗 https://ir.sdsoptic.com/raporty/espi-20-2023-rozpoczecie-realizacji-nowego-kamienia-milowego-przy-wspolpracy-z-philips-i-csem-oraz-pozyskanie-finansowania-w-ramach-programu-medphabespi-20-2023/

EIC - The European Innovation Council

16/06/2023

Bio International Convention wrap-up video is ready.
Check it and find out, how the team promote technology this year in Boston!

08/06/2023

Check out the wrap-up by 🇺🇲💪🌎

07/06/2023

Day 2 at the Conference in Boston.
It was great to meet with our friends and supporters of novel medical technologies. Togerher we are building the future of Medicine and shaping new landscape of biotechnological world.

07/06/2023

at BIO International Convention 💪🇵🇱🇺🇲

First day at BIO International Convention behind us. 💪 It was great to meet again with peers, colleages and global power players in the biotech and pharma industry at the world's most influential biotech meeting.

Great thanks to organizers Polska Agencja Inwestycji i Handlu - PAIH , Central European BioForum ,

We are keeping our fingers crossed for every company in Polish Biotech Stand 🤞

28/04/2023

🔔 Just a few days ago we have received a summary report for the first part of the clinical trials!
Some time before we also informed you about the last operation and examination of the patient in this part of the clinical trial.
👉 NOW our CRO advisor confirmed the conclusions of the preliminary report from March and provided us with more details on the first part of the study.
▪️ A total of 22 patients (7 HER2-positive and 15 HER2-negative) qualified for the study, 21 of them will be included in the statistics of the report.
▪️ Part 1 of the study was conducted entirely in one clinical center
▪️ No adverse events related to the product or the study procedure have been reported.
▪️ The feedback received after test with the probe were used to improve the examination procedure.

The second part of the is ahead of us. We prepared a following plan for next couple of months:
1️⃣ Development of a special algorithm to analyze and evaluate the data we will gather in part two. Signing of contracts with 5 clinical centers. Submitting proposals for technical improvements to the URPL.
2️⃣ Production of own biosensors using own clean room infrastructure.
3️⃣ Clinical trial of 192 patients in ambulatory settings.

ℹ️ The aim of Part 2 of the study is to confirm the correlation between the HER2
receptor concentration detected with the inProbe diagnostic probe and with the
standard method (IHC/FISH) and to assess the safety of the inPROBE diagnostic
microprobe in determining the HER2 receptor status in women with high breast
cancer risk, in a single inProbe diagnostic test prior to the coarse-needle biopsy
(BG) procedure.

_______________________
European Commission CORDIS_EU EIC - The European Innovation Council EIT Health Enterprise Europe Network SDS Optic

07/04/2023

Happy Easter Everyone! 🐇

🇵🇱 Wreszcie Wielkanoc! 🐣

Pozwól, że z tej okazji złożymy Ci najserdeczniejsze życzenia Tobie i Twoim bliskim. Niech te święta wypełnią serca miłością, nadzieją i radością.

🐇 Ten szczególny czas w roku zawsze podkreśla ważność naszej wizji.
Pozostajemy wierni naszej misji tworzenia innowacyjnych rozwiązań diagnostycznych dla poprawy zdrowia i ratowania życia.
Jesteśmy wdzięczni za Twoje zaufanie i wsparcie, dzięki któremu możemy osiągać znaczące postępy w naszych pracach badawczych i rozwojowych.

Z niecierpliwością czekamy na naszą dalszą współpracę, aby razem budować lepszą i jaśniejszą przyszłość.
Niech ta Wielkanoc przyniesie Ci nową dawkę energii i inspiracji do realizacji marzeń i osiągania celów.

Wesołych Świąt Wielkanocnych!
- Zespół SDS Optic

🇬🇧 It's Easter!

Let us extend our warmest wishes to you and your loved ones.
May the holiday celebration fill your hearts with love, hope, and happiness.

This time of the year always underline our vision.
We remain committed to our mission of developing innovative diagnostics solutions to improve human health and well-being.
We are grateful for your trust and support, which has enabled us to make significant progress in our research and development efforts.

We look forward to continuing our collaboration and working together towards a brighter future.
May this Easter season bring you renewed energy and inspiration to pursue your dreams and achieve your goals.

Happy Easter!
- SDS Optic Team

07/03/2023

🔥 We have just received a confirmation of completion of the final operation in safety phase of of the , biosensor and medical device designed to assess HER2 receptor overexpression in a population of women with breast cancer.

The document received from CRO confirms the correct conduct of the examination during surgery on 18 patients with a specific disease profile. Under the safety phase, a total of 21 cancer patients were examined, including 6 HER2-positive patients, 12 HER2-negative patients and 3 patients who, as a result of the monitoring checks, were not included in the statistics of STAGE I of the clinical trial.

The preliminary report received shows that no adverse events related to the inPROBE device or examination procedure, which is a confirmation of the safety of the SDS Optic's technology.

Document we received is informative and does not constitute an official final clinical report from STAGE I of the clinical trial of the inPROBE.

In stage I of the clinical study we want to confirm the safety of the inPROBE microprobe in the diagnosis of patients with HER2-positive and HER2-negative breast cancer and to analyze the correlation of the receptor status around the tumor and in the tumor itself.

In the following months, all data we've collected will be processed and analyzed. We will develop an algorithm for the analysis and evaluation of the data, which will be collected in the planned second phase of the clinical trial.

Final report from the Safety Phase of the clinical trial, which we are expecting to receive in upcoming months, will enable the start of the Efficacy Phase. This stage will consist of 192 outpatients. The aim of STAGE II will be to confirm the accuracy and validation of the inPROBE technology in HER2-positive breast cancers. This part of the study is planned for about 6 months from the official start.

🔗More about inPROBE: https://inprobe.com/
🔗More about SDS Optic: https://sdsoptic.pl/en/main-en/

_________________________________
European Commission EIC - The European Innovation Council CORDIS_EU EIT Health Enterprise Europe Network Enterprise Europe Network Polska INNOventure Polska Agencja Rozwoju Przedsiębiorczości Polska Agencja Inwestycji i Handlu - PAIH Narodowe Centrum Badań i Rozwoju Euronews English Polish Medical Devices - Branżowy Program Promocji Klaster Lubelska Medycyna World Health Organization (WHO)